Liminatus Pharma Shares Hit New Peak Post Nasdaq Approval
Investors React Positively After Listing Status Restored
Liminatus Pharma Inc. (NASDAQ: LIMN) witnessed an impressive rally in its share price on June 5, 2025, reaching an all-time high of \$28.80. This upward movement followed the company’s official announcement confirming it had successfully regained compliance with Nasdaq’s listing criteria. The development reignited investor enthusiasm and strengthened market sentiment regarding the company’s outlook.
As trading progressed, the stock soared, touching a peak of \$28.80 before experiencing a low of \$15.52 and eventually settling at a closing price of \$24.60. Compared to previous sessions, the surge represented a substantial gain. Approximately 4.34 million shares changed hands during the session, underscoring heightened trading activity and investor interest.
The company’s return to compliance with Nasdaq’s listing standards played a central role in the stock’s strong performance. Regaining this status ensures that Liminatus continues to be listed on a major U.S. stock exchange, which enhances the company’s visibility and reputation in the biotech investment community.
By meeting Nasdaq’s financial and operational benchmarks once again, Liminatus Pharma has demonstrated improved business fundamentals and governance. This renewed standing positions the pharmaceutical firm for further advancement as it competes within a challenging yet opportunity-rich market.
The milestone not only eliminates previous delisting concerns but also signals to stakeholders that the company is back on stable footing, which could potentially attract new institutional investors and partnerships going forward.
Summary
Liminatus Pharma shares surged to an all-time high of \$28.80 on June 5, 2025, after the company announced that it had met Nasdaq’s listing requirements once again. This significant update boosted investor confidence and was a key driver behind the day’s remarkable price increase.
The image added is for representation purposes only
